NMRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.332

-10.17%

-0.317

-24.6%

-0.263

-20.2%

Estimates Revision

Stock Price

Go Up

+29.28%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is 8.67 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

1 Sell

Moderate Buy

Current: 1.965

Low

3.00

Averages

8.67

High

18.00

Current: 1.965

Low

3.00

Averages

8.67

High

18.00

Stifel

Hold

maintain

$2 -> $3

2025-11-17

Reason

Stifel

Price Target

$2 -> $3

2025-11-17

maintain

Hold

Reason

Stifel raised the firm's price target on Neumora Therapeutics to $3 from $2 and keeps a Hold rating on the shares following Q3 earnings and hosting management at the firm's annual Healthcare Conference. NMRA-511's Phase 1b readout in AD agitation is expected to readout by year-end and expectations are low despite favorable initial tolerability data, making this catalyst "arguably upside-skewed," the analyst tells investors.

Needham

Buy

maintain

$6 -> $8

2025-10-28

Reason

Needham

Price Target

$6 -> $8

2025-10-28

maintain

Buy

Reason

Needham raised the firm's price target on Neumora Therapeutics to $8 from $6 and keeps a Buy rating on the shares. The firm is more positive on Neumora following its R&D Investor Event which underscored its broad pipeline beyond navacaprant leveraging best in class pharmacology, and brain penetrant chemistry, targeting novel mechanisms with potential to improve current standard of care, the analyst tells investors in a research note.

Guggenheim

Neutral -> Buy

upgrade

$14

2025-10-27

Reason

Guggenheim

Price Target

$14

2025-10-27

upgrade

Neutral -> Buy

Reason

Guggenheim upgraded Neumora Therapeutics to Buy from Neutral with a $14 price target following the "compelling" preclinical obesity data reported by the company. The firm views the company's NLRP3i program in obesity and related disorders as "a clear driver to value creation," the analyst tells investors.

JPMorgan

Neutral -> Underweight

downgrade

2025-09-16

Reason

JPMorgan

Price Target

2025-09-16

downgrade

Neutral -> Underweight

Reason

JPMorgan downgraded Neumora Therapeutics to Underweight from Neutral without a price target. The company's Phase 3 KOASTAL-1 trial evaluating navacaprant as a monotherapy treatment in major depressive disorder failed to hit its primary endpoint or key secondary endpoint earlier this year, the analyst tells investors in a research note. The firm believes Neumora shares will continue to underperform peers into the Phase 3 KOASTAL-2 and KOASTAL-3 trial readouts.

Mizuho

Graig Suvannavejh

Outperform

maintain

$4 -> $5

2025-07-16

Reason

Mizuho

Graig Suvannavejh

Price Target

$4 -> $5

2025-07-16

maintain

Outperform

Reason

Mizuho analyst Graig Suvannavejh raised the firm's price target on Neumora Therapeutics to $5 from $4 and keeps an Outperform rating on the shares following last week's introduction of NMRA-861. The firm projects a U.S. launch in 2034 and risk-unadjusted NMRA-861 sales of $1.2B in 2037. It sees a favorable risk/reward at current share levels.

Needham

Ami Fadia

Strong Buy

Reiterates

2025-04-10

Reason

Needham

Ami Fadia

Price Target

2025-04-10

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Neumora Therapeutics Inc (NMRA.O) is -1.77, compared to its 5-year average forward P/E of -4.87. For a more detailed relative valuation and DCF analysis to assess Neumora Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.87

Current PE

-1.77

Overvalued PE

-1.24

Undervalued PE

-8.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.64

Current EV/EBITDA

-1.07

Overvalued EV/EBITDA

-0.28

Undervalued EV/EBITDA

-7.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 327.95% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NMRA News & Events

Events Timeline

No data

News

4.0

12-01Benzinga

Analyst Recognizes Potential in Neumora's Growing Obesity and Metabolic Portfolio

4.0

12-01SeekingAlpha

Neumora Receives Upgrade from RBC Capital Markets Due to Obesity and Parkinson's Drug Potential

4.0

12-01Benzinga

Chevron Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Monday

People Also Watch

Frequently Asked Questions

What is Neumora Therapeutics Inc (NMRA) stock price today?

The current price of NMRA is 1.965 USD — it has decreased -5.98 % in the last trading day.

What is Neumora Therapeutics Inc (NMRA)'s business?

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

What is the price predicton of NMRA Stock?

What is Neumora Therapeutics Inc (NMRA)'s revenue for the last quarter?

Neumora Therapeutics Inc revenue for the last quarter amounts to -52.70M USD, decreased -31.24 % YoY.

What is Neumora Therapeutics Inc (NMRA)'s earnings per share (EPS) for the last quarter?

Neumora Therapeutics Inc. EPS for the last quarter amounts to -46649000.00 USD, increased 39.32 % YoY.

What changes have occurred in the market's expectations for Neumora Therapeutics Inc (NMRA)'s fundamentals?

The market is revising No Change the revenue expectations for NMRA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 29.28%.

How many employees does Neumora Therapeutics Inc (NMRA). have?

Neumora Therapeutics Inc (NMRA) has 110 emplpoyees as of December 15 2025.

What is Neumora Therapeutics Inc (NMRA) market cap?

Today NMRA has the market capitalization of 355.17M USD.